Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

April 18, 2001

Last Updated Date

June 23, 2005

Start Date ^†

Current Primary Outcome Measures ^†

Identification of homogenous subgroups within total population of cocaine dependent adults

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00015275 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Original Secondary Outcome Measures ^†

Descriptive Information

Brief Title ^†

Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9

Official Title ^†

Pathophysiological Subtyping of Abnormalities in Cocaine Dependence

Brief Summary

The purpose of this study is to define pathophysiological subtypes of abnormalities in subjects with cocaine dependence.

Detailed Description

The objective of this study is to define subgroups of patients with differential treatment outcome on the basis of differential baseline electrophysiological clusters.

Study Phase

Phase IV

Study Type ^†

Interventional

Study Design ^†

Diagnostic, Open Label

Condition ^†

Cocaine-Related Disorders
Substance-Related Disorders

Intervention ^†

Behavioral: Cocaine-Related Disorders

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria: Cocaine dependence. Seeking residential treatment.

Gender

Male

Ages

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00015275

Responsible Party

Secondary IDs ^††

Y01-5-0013-9

Study Sponsor ^†

National Institute on Drug Abuse (NIDA)

Collaborators ^††

New York MDRU

Investigators ^†

Principal Investigator:

John Rotrosen, M.D.

New York MDRU

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

December 2002

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.